A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites

Trial Profile

A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs AZD 9150 (Primary)
  • Indications Ascites; Gastrointestinal cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top